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Background: Increasing evidence supports interplay between aldosterone and parathyroid hormone (PTH), which may aggravate 
cardiovascular complications in various heart diseases. Negative structural cardiovascular remodeling by primary aldosteronism 
(PA) is also suspected to be associated with changes in calcium levels. However, to date, few clinical studies have examined how 
changes in calcium and PTH levels influence cardiovascular outcomes in PA patients. Therefore, we investigated the impact of al-
tered calcium homeostasis caused by excessive aldosterone on cardiovascular parameters in patients with PA. 
Methods: Forty-two patients (mean age 48.8±10.9 years; 1:1, male:female) whose plasma aldosterone concentration/plasma renin 
activity ratio was more than 30 were selected among those who had visited Severance Hospital from 2010 to 2014. All patients un-
derwent adrenal venous sampling with complete access to both adrenal veins. 
Results: The prevalence of unilateral adrenal adenoma (54.8%) was similar to that of bilateral adrenal hyperplasia. Mean serum 
corrected calcium level was 8.9±0.3 mg/dL (range, 8.3 to 9.9). The corrected calcium level had a negative linear correlation with 
left ventricular end-diastolic diameter (LVEDD, ρ=–0.424, P=0.031). Moreover, multivariable regression analysis showed that the 
corrected calcium level was marginally associated with the LVEDD and corrected QT (QTc) interval (β=–0.366, P=0.068 and 
β=–0.252, P=0.070, respectively). 
Conclusion: Aldosterone-mediated hypercalciuria and subsequent hypocalcemia may be partly involved in the development of car-
diac remodeling as well as a prolonged QTc interval, in subjects with PA, thereby triggering deleterious effects on target organs addi-
tively. 
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INTRODUCTION
Primary aldosteronism (PA) is the most frequent form of sec-
ondary hypertension (HTN) [1]. PA accounts for up to 20% of 
patients with resistant HTN [2]. Moreover, one study demon-
strated that about 13% of a normotensive cohort had biochemi-
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cally confirmed PA, and that these patients were at a higher risk 
for developing incident HTN [3]. Prolonged elevated aldoste-
rone concentrations are known to be associated with an in-
creased risk of myocardial infarction, atrial fibrillation, stroke, 
and chronic kidney disease [4,5]. In addition, an excess of aldo-
sterone can itself lead to a greater number of cardiovascular 
complications, independent of blood pressure (BP), compared 
to that seen with essential HTN [4,6]. Beyond its role in affect-
ing BP and intravascular volume, PA may influence metabolic 
alterations [7] and oxidative stress, thereby damaging target or-
gans [8,9].
Parathyroid hormone (PTH) plays an important role in bone 
and mineral metabolism, and its secretion from the parathyroid 
gland is dependent on serum calcium levels [10]. Aldosterone 
may impact calcium and mineral homeostasis by enhancing re-
nal loss of calcium and magnesium, thereby contributing to hy-
pocalcemia and subsequent secondary hyperparathyroidism 
(SHPT) [11,12]. An increasing body of evidence has shown an 
interplay between the renin-angiotensin-aldosterone system 
(RAAS) and PTH, which may potentiate cardiovascular risk in 
certain heart diseases, such as congestive heart failure [13,14]. 
However, there is a lack of data on how hypocalcemia practical-
ly affects cardiovascular parameters, such as electrocardiogra-
phy (ECG) or echocardiography, in PA patients.
Given this background, we hypothesized that the changes in 
calcium metabolism that occur in PA may effect cardiac struc-
tural or functional changes independent of plasma aldosterone 
levels. 
METHODS
Subjects 
Forty-two patients with PA (mean age 48.8±10.9 years) were 
enrolled from among all patients who visited the HTN clinic at 
Severance Hospital from 2010 to 2014. The inclusion criteria 
were as follows: a plasma aldosterone concentration (PAC)/
plasma renin activity (PRA) ratio of more than 30; a diagnosis 
of PA confirmed using a saline loading test; available blood 
samples for measuring PTH levels. A positive result was de-
fined as a post-saline loading PAC of over 8.5 ng/dL [15]. All 
patients underwent sequential adrenal venous sampling (AVS) 
with complete access to both adrenal veins. Moreover, serum 
PTH levels were measured by immunoradiometric assays; the 
reference range was 10 to 57 pg/mL. The measurement of se-
rum 25-hydroxyvitamin D (25(OH)D) levels was performed in 
40 patients (95.2%). The present study protocol was reviewed 
and approved by the Institutional Review Board of Yonsei Uni-
versity College of Medicine, and all participants signed consent 
forms (approval no. 4-2012-0544). All investigations were per-
formed in accordance with the principles of the Declaration of 
Helsinki. 
Subtype classification
In all patients, adrenal computed tomography (CT) was con-
ducted in three phases with a 64-channel multidetector CT scan-
ner (Discovery CT750HD, GE Healthcare, Milwaukee, WI, 
USA) before AVS. The CT and AVS protocols were the same as 
described in our previous study [16]. All patients underwent C-
arm CT (Axiom Artis dTA, Siemens, Erlangen, Germany)-as-
sisted sequential bilateral AVS with 100% successful access to 
both adrenal veins during continuous intravenous infusion of 
tetracosactide (Cynacten, Dalim Biotech, Seoul, Korea). C-arm 
CT was used because it improves accuracy of right adrenal vein 
catheterization during AVS. All AVS procedures were per-
formed in the angiography room in which C-arm CT was avail-
able. When C-arm CT images revealed the proper catheter posi-
tion, blood sampling was conducted. Vein samples were ob-
tained at least 30 minutes after initiation of intravenous tetraco-
sactide administration. Adequate catheterization during AVS 
was defined as a cortisol ratio in blood sampled from the adre-
nal vein and inferior vena cava of equal to or more than 3:1. In 
addition, when the adrenal venous blood cortisol-corrected al-
dosterone ratio was greater than 2.6 after tetracosactide stimula-
tion, a unilateral lesion was considered to be present on the 
high-value side [15].
Assessment of cardiac structure, function, and electrical 
activity 
Echocardiography was conducted in 28 subjects (66.7%). Com-
prehensive echocardiographic assessments were conducted by 
three experienced sonographers, who had no knowledge of the 
clinical data, using commercially available ultrasound systems 
(Sonos 5500, Philips Medical Systems, Andover, MA, USA; or 
Vivid Seven, GE Vingmed Ultrasound, Horten, Norway). All 
echocardiographic parameters were measured according to rec-
ommendations from the American Society of Echocardiography 
[17]. The echocardiography protocol was the same as described 
in our previous study [8]. The following parameters were evalu-
ated: left ventricular ejection fraction (LVEF, %), left ventricu-
lar end-diastolic diameter (LVEDD, mm), left ventricular end-
systolic diameter (LVESD, mm), end-diastole interventricular 
septum diameter (IVSd, mm), end-diastole left ventricular (LV) 
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posterior wall diameter (PWd, mm), left ventricular mass index 
(LVMI, g), left atrial volume index (LAVI, mL/m2), early and 
late mitral flow velocities (E and A, m/sec), deceleration time 
(DT) of E velocity (msec), and the ratio of E to early diastolic 
mitral annular velocity (E/E’ ratio). Systolic function was mea-
sured by LVEF. Additionally, the presence of cardiac remodel-
ing regarding structural abnormality was assessed using 
LVEDD, LVESD, IVSd, PWd, LV mass, LVMI, and LAVI; E 
and A velocities, DT, and E/E’ ratio were used as parameters for 
diastolic function. ECG was carried out in all patients. Twelve-
lead ECGs were recorded by digital ECG instruments (General 
Electric Healthcare, Milwaukee, WI, USA), and we investigated 
the corrected QT (QTc) interval as a marker for representing the 
risk of arrhythmia in patients with PA.
Statistical analysis 
Statistical analyses were conducted using IBM SPSS version 
23.0 for Windows (IBM Co., Armonk, NY, USA). Due to the 
small number of patients in our study, some data were analyzed 
using nonparametric tests. Student t tests and chi-square tests 
were used to compare differences in continuous and categorical 
variables, respectively, between unilateral aldosterone-produc-
ing adenoma (APA) and bilateral adrenal hyperplasia (BAH) 
patients. The relationships between each echocardiographic pa-
rameter and PAC or corrected calcium level were determined by 
using the Spearman partial correlation after adjusting for age 
and sex. Also, multivariate regression analyses were used to ex-
amine the associations between corrected calcium level and 
each echocardiographic parameter or QTc interval in those with 
PA. P values <0.05 were considered statistically significant. 
RESULTS
The baseline characteristics of all subjects are presented in Table 
1. There were 21 males and 21 females in our cohort. The prev-
alence of unilateral APA (54.8%) was similar to that of BAH. 
The mean BP was 149/91 mm Hg, and mean duration of HTN 
was about 7.6 years. In addition, mean PTH and serum calcium 
Table 1. Baseline Characteristics
Characteristic Total (n=42)
Age, yr 48.8±10.9
Sex, male/female 21/21
HTN duration, yr 7.6±7.9
Systolic blood pressure, mm Hg 149.3±18.5
Diastolic blood pressure, mm Hg 90.8±12.2
Heart rate, bpm 74.0±11.4
Serum potassium, mmol/L 3.53±0.52
tCO2, mmol/L 28.7±3.3
PAC, ng/dL 33.8±23.5
PRA, ng/mL/hr 0.24±0.24
ARR 341.8±951.4
PAC after saline loading test, ng/dL 19.6±16.3
PTH, pg/mL 56.1±26.5
25(OH)D, ng/mL 12.8±6.2
Corrected calcium, mg/dL 8.9±0.3
QTc interval, msec 431.7±23.9
Values are expressed as mean±standard deviation.
HTN, hypertension; tCO2, total carbon dioxide; PAC, plasma aldoste-
rone concentration; PRA, plasma renin activity; ARR, aldosterone-renin 
ratio; PTH, parathyroid hormone; 25(OH)D, 25-hydroxyvitamin D; 
QTc, corrected QT.  
Table 2. Differences in Aldosterone and Corrected Calcium 
Levels between Patients with APA and BAH
Variable APA (n=23)
BAH 
(n=19)
P value
Age, yr 46.5±11.5 51.5±9.8 0.146
Sex, male/female 9/14 12/7 0.121
HTN duration, yr 6.6±4.6 9.1±11.0 0.406
Systolic blood pressure, 
mm Hg 
149.7±18.8 148.9±18.6 0.901
Diastolic blood pressure, 
mm Hg
89.8±13.1 92.0±11.1 0.574
Heart rate, bpm 72.3±10.7 75.5±12.2 0.438
Serum potassium, mmol/L 3.46±0.57 3.63±0.43 0.314
tCO2, mmol/L 29.1±3.6 28.2±2.9 0.458
PAC, ng/dL 42.6±27.0 23.2±12.1 0.004
PRA, ng/mL/hr 0.23±0.22 0.25±0.26 0.857
ARR 527.1±1,233.4 90.4±60.6 0.141
PAC after saline loading 
test, ng/dL
27.2±18.6 10.4±4.9 <0.001
PTH, pg/mL 61.9±30.7 49.1±18.8 0.122
25(OH)D, ng/mL 12.1±5.0 13.6±7.3 0.451
Corrected calcium, mg/dL 8.8±0.3 9.0±0.3 0.036
QTc interval, msec 439.4±25.3 422.3±18.6 0.019
Values are expressed as mean±standard deviation.
APA, aldosterone-producing adenoma; BAH, bilateral adrenal hyper-
plasia; HTN; hypertension; tCO2, total carbon dioxide; PAC, plasma al-
dosterone concentration; PRA, plasma renin activity; ARR, aldoste-
rone-renin ratio; PTH, parathyroid hormone; 25(OH)D, 25-hydroxyvi-
tamin D; QTc, corrected QT. 
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levels were approximately 56.1 pg/mL and 8.9 mg/dL, respec-
tively. 
Differences in aldosterone and corrected calcium levels 
between APA and BAH patients
Differences in PAC, serum PTH, and calcium levels between 
APA and BAH patients are described in Table 2. Even though 
the differences in BP, serum potassium, and the PAC/PRA ratio 
between APA and BAH subjects were not definite, there were 
significant differences in baseline PAC and PAC levels after the 
saline loading test between the two groups. Moreover, serum cor-
rected calcium levels were significantly lower in APA subjects 
when compared with BAH subjects (8.8 mg/dL vs. 9.0 mg/dL, 
respectively); however, no meaningful differences were found 
for PTH or serum 25(OH)D levels between the two groups. In 
addition, patients with APA showed a more prolonged QTc in-
terval than those with BAH.
Associations between PAC and corrected calcium levels 
and echocardiographic parameters in patients with PA
We evaluated whether aldosterone or hypocalcemia could affect 
each echocardiographic parameter in patients with PA. As 
shown in Table 3, PAC was negatively correlated with LVEF 
and DT (ρ=–0.396, P=0.046 and ρ=–0.422, P=0.036, respec-
tively), but showed positive correlations with LVESD and A ve-
locity (ρ=0.396, P=0.045 and ρ=0.474, P=0.022, respectively) 
even after the adjustments for age and sex, indicating that aldo-
sterone can have an impact on cardiac remodeling, such as 
structural abnormalities and diastolic function. Meanwhile, the 
corrected calcium level had a negative linear correlation with 
LVEDD (ρ=–0.424, P=0.031). 
Associations between corrected calcium levels and 
echocardiographic parameters or the QTc interval in 
patients with PA
To confirm whether alterations in calcium homeostasis associat-
ed with excessive aldosterone exert influence on echocardio-
graphic parameters or the QTc interval in subjects with PA, 
multivariable regression analyses were performed (Table 4). As 
aldosterone excess is known to lead to metabolic alkalosis as 
well as increased urinary calcium loss, corrected calcium, PAC, 
and total CO2 were used for the adjustment. As a result, the neg-
ative association between serum corrected calcium levels and 
LVEDD remained marginally significant, even after adjusting 
for PAC and total CO2 (β=–0.366, P=0.068). Also, corrected 
calcium levels showed a trend towards being negatively associ-
Table 3. Association between Aldosterone or Corrected Calcium Levels and Echocardiographic Parameters in Patients with Primary 
Aldosteronism 
Variable Correlation coefficient (PAC) P value
Correlation coefficient 
(corrected calcium) P value
Parameters for structural abnormality
   LVEF, % –0.396 0.046a –0.079 0.700
   LVEDD, mm 0.270 0.182 –0.424 0.031a
   LVESD, mm 0.396 0.045a –0.227 0.266
   IVSd, mm –0.120 0.559 0.120 0.561
   PWd, mm –0.104 0.614 –0.123 0.549
   LV mass, g 0.182 0.405 –0.153 0.487
   LVMI, g/m2 0.037 0.867 –0.351 0.101
   LAVI, mL/m2 0.050 0.813 –0.094 0.656
Parameters for diastolic function
   E velocity, m/sec 0.209 0.316 –0.150 0.475
   A velocity, m/sec 0.474 0.022a 0.251 0.248
   Deceleration time, msec –0.422 0.036a –0.242 0.244
   E/E’ ratio 0.250 0.228 –0.065 0.759
PAC, plasma aldosterone concentration; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular 
end-systolic diameter; IVSd, interventricular septum diameter; PWd, posterior wall diameter; LV, left ventricular; LVMI, left ventricular mass index; 
LAVI, left atrial volume index.
aP<0.05, after adjusting for age and sex. 
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ated with the QTc interval, although the relationship between 
corrected calcium levels and the QTc interval was only margin-
ally significant (β=–0.252, P=0.070). The explanation powers 
(R-Square) of each model were 0.246 in the model of LVEDD 
and 0.391 in the model for QTc interval, respectively.
DISCUSSION
Recently, the significance of HTN and osteoporosis as public 
health problems has been emphasized, because the elderly pop-
ulation is rapidly rising all over the world. Aldosterone excess 
has been found to be associated with cardiovascular complica-
tions and organ damage [4,18]. Monticone et al. [18] showed 
that patients with PA were not only at an increased risk of car-
diovascular diseases, including atrial fibrillation, coronary ar-
tery disease, heart failure, LV hypertrophy, and stroke, but also 
of metabolic disorders, such as diabetes mellitus and metabolic 
syndrome, compared with patients with essential HTN. Further-
more, increasing evidence has shown that PA is a risk factor for 
fractures, independent of BP [19,20], and contributes to detri-
mental effects on bone quality rather than bone mineral density 
via changes in mineral homeostasis [21]. In this regard, it is im-
portant to understand the effects of changes in calcium and PTH 
levels on cardiovascular outcomes in PA patients. 
Calcium, which is a crucial structural component of bone and 
a major regulator in myocardial contraction, plays a number of 
essential roles in the normal physiological process of our body, 
including various cellular signaling cascades [22]. A meta-anal-
ysis recently reported that circulating calcium is related to vas-
cular disease and mortality [23]. Foley et al. [24] also had shown 
that a hazard ratio of stroke (1.37; 95% confidence interval, 1.28 
to 1.46) according to standard deviation of corrected calcium 
level in a prospective and community-based study has increased. 
In addition, primary hyperparathyroidism (PHPT), which is 
usually characterized by hypercalcemia, has been associated 
with increased mortality, as well as cardiovascular morbidity 
[25]. Interestingly, the hypertensive aspect of PHPT is known to 
be linked to excessive aldosterone levels. The level of PTH is 
positively associated with aldosterone levels in PHPT; preoper-
ative PTH levels over 100 ng/mL may be an independent pre-
dictor for abnormally elevated PAC [26]. Barkan et al. [27] also 
reported the case of a 60-year-old woman with PHPT exhibiting 
HTN and hypokalemia, similar to that seen in PA. 
Furthermore, negative structural cardiovascular remodeling 
by PA might be related to elevated levels of PTH [28]. Cumula-
tive evidence points to a bidirectional interaction between PTH 
and aldosterone, which can aggravate target organ damage [29]. 
PTH can increase aldosterone secretion from the adrenal gland 
not only directly, but also indirectly by activating the RAAS 
[30,31]. In the setting of chronic heart failure, secondary hyper-
aldosteronism may cause salt retention and SHPT due to urinary 
loss of calcium and magnesium [11]; in PA, hypercalciuria and 
hypocalcemia caused by excessive aldosterone stimulate the se-
cretion of PTH, which, in turn, triggers aldosterone secretion 
[11,12]. Chronic mineralocorticoidism can cause oxidative stress 
and endothelial dysfunction, which can result in damage to ves-
sels and cardiomyocytes [32]. Meanwhile, PTH can have dele-
terious effects on the heart: it can stimulate cardiomyocyte hy-
pertrophy by activating protein kinase A or C [33] and induce 
cardiac arrhythmias through calcium overloading [34]. PTH-
mediated calcium overloading has also been linked to an induc-
tion of oxidative stress in the mitochondria of cardiomyocytes, 
thereby contributing to necrosis and fibrosis of the heart [28]. 
These mechanisms may help explain the finding that aldoste-
rone and PTH mutually affect cardiovascular mortality risk, as 
reported by Tomaschitz et al. [35]. However, although increas-
ing evidence has demonstrated that hyperparathyroidism can 
lead to deleterious consequences for heart failure [14,29], few 
clinical studies have examined how alterations in calcium me-
tabolism impact cardiovascular parameters in patients with PA.
In this study, APA patients had significantly lower serum cor-
rected calcium levels and more prolonged QTc intervals than 
those with BAH, even though the differences in PTH levels be-
tween the two groups were not found. In a previous study, Cec-
coli et al. [36] reported a higher level of PTH in the APA group 
than in the BAH group, although the statistical difference in PTH 
Table 4. Factors Associated with LVEDD and the QTc Interval 
in Patients with Primary Aldosteronism
Parameter β 95% CI P value
LVEDD
   PAC, ng/dL 0.373 –0.015 to –0.161 0.099
   Corrected calcium, mg/dL –0.366 –9.925 to 0.389 0.068
   tCO2 –0.477 –1.158 to –0.024 0.042
QTc interval
   PAC, ng/dL 0.574 0.288 to –0.872 <0.001
   Corrected calcium, mg/dL –0.252 –40.466 to 1.680 0.070
   tCO2 –0.148 –3.228 to 1.030 0.301
LVEDD, left ventricular end-diastolic diameter; QTc, corrected QT; CI, 
confidence interval; PAC, plasma aldosterone concentration; tCO2, total 
carbon dioxide. 
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levels between the two groups was not observed. Moreover, 
considering that APA patients usually have higher aldosterone 
levels than BAH patients, our inconsistent results regarding PTH 
levels may be due to the small number of subjects used in the 
current study. The next question was how aberration in calcium 
homeostasis regarding aldosterone excess affects each echocar-
diographic parameter or QTc interval in patients with PA. 
According to our previous study [8], various inflammatory 
markers in relation to the oxidative stress in PA can affect some 
of echocardiographic parameters which reflect cardiac structure 
(LAVI, LVESD, IVSd, and LV mass) and diastolic function (A 
and E’ velocities). On the other hand, this study showed that 
PAC was related to LVEF, LVESD, A velocity, and DT after ad-
justing for age and sex. In addition, the corrected calcium level 
was negatively correlated with LVEDD after adjusting for age 
and sex (ρ=–0.424, P=0.031), suggesting that aldosterone-in-
duced hypocalcemia may have an influence on structural abnor-
malities in patients with PA. Intriguingly, despite the small 
number of population, multivariable regression analyses also 
demonstrated that corrected calcium levels showed a trend to-
wards being negatively associated with LVEDD, even after ad-
justment for confounding factors (β=–0.366, P=0.068). We 
could observe such possibility that corrected calcium levels may 
aggravate structural abnormalities, thereby developing cardiac 
remodeling. 
As an aforementioned previous study showed, atrial fibrilla-
tion had the highest odds ratio among the cardiovascular com-
plications of PA patients [18]. Excessive aldosterone can influ-
ence mineral homeostasis [37], and sodium excretion is corre-
lated with urinary calcium [38]. Additionally, hypercalciuria in 
hyperaldosteronism might be attributed to reduced sodium reab-
sorption in aldosterone-insensitive tubular areas [39]. Therefore, 
we speculated that altered calcium metabolism accompanied by 
aldosterone excess might play an important role in raising the 
risk of arrhythmias, including atrial fibrillation, although the 
negative association between corrected calcium levels and QTc 
interval was only marginally significant (β=–0.252, P=0.070).
To our knowledge, this is the first clinical study to analyze 
how changes in calcium levels impact cardiovascular parame-
ters using ECG and echocardiography in patients with PA. Our 
data support the hypothesis that altered calcium homeostasis 
due to aldosterone excess might act as a potential aggravating 
factor for the development of cardiovascular complications and 
ultimately triggering deleterious effects on target organs. How-
ever, our study also has some limitations. First, this study has a 
cross-sectional design. Thus, it is difficult to confirm causality 
between factors. Second, the sample size of this study was 
small. That might be why we could not observe significant as-
sociations between corrected calcium levels and LVEDD or 
QTc interval after adjusting for confounding factors. However, 
our result is quite valuable that these relationships were margin-
ally significant in spite of the small number of population. Ad-
ditionally, statistic problems such as multicollinearity of the 
multivariable regression analyses were not found, although the 
explanation power of these models was somewhat low. Third, 
we did not evaluate urine calcium or serum and urine magne-
sium levels. Considering mean value of serum 25(OH)D in this 
study, most of patients with PA may have vitamin D deficiency. 
Particularly, urinary calcium excretion may be very helpful to 
gain insight into the effects of aberrations in serum calcium, to-
gether with elevated PTH levels, on clinical cardiac outcomes 
in PA patients. Finally, echocardiography was conducted by 
three sonographers. Hence, inter-individual variations among 
their results are likely. 
In conclusion, although the associations between corrected 
calcium levels and LVEDD or QTc interval were only margin-
ally significant, our results suggest that aldosterone-mediated 
hypercalciuria and subsequent hypocalcemia may be in part in-
volved in the development of structural cardiovascular remodel-
ing and a prolonged QTc interval, thereby exacerbating target 
organ damage additively in subjects with PA. Therefore, a fu-
ture, large, well-designed research study with long-term follow-
up is required to explain the effects of altered calcium homeo-
stasis on adverse cardiovascular outcomes in PA patients. 
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